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Abstract. Non-viral delivery systems are generally of low efficiency, which limit their use 
in gene therapy and editing applications. We previously developed a technology termed 
glycosaminoglycan (GAG)-binding enhanced transduction (GET) to efficiently deliver a 
variety of cargoes intracellularly; our system employs GAG-binding peptides which 
promote cell targeting, and cell penetrating peptides (CPPs) which enhance endocytotic 
cell internalization. Herein, we describe a further modification by combining gene delivery 
and magnetic targeting with the GET technology. We associated GET peptides, plasmid 
(p)DNA and iron oxide superparamagnetic nanoparticles (MNPs); allowing rapid and 
targeted application of GET-mediated uptake by application of static magnetic fields in 
NIH3T3 cells. This produced effective transfection levels (significantly higher than control) 
with seconds to minutes of exposure, and localized gene delivery two orders of magnitude 
higher in targeted over non-targeted cell monolayers using magnetic fields (in a 15 minute 
exposure delivering GFP reporter pDNA). More importantly, high cell membrane targeting 
by GET-DNA and MNP co-complexes and magnetic fields allowed further enhancement 
to endocytotic uptake, meaning that the nucleic acid cargo was rapidly internalized 
beyond that of GET complexes alone (GET-DNA). Magnetofection by MNPs combined 
with GET-mediated delivery allows magnetic field-guided local transfection in vitro, and 
could facilitate focused gene delivery for future regenerative and disease-targeted 
therapies in vivo. 
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1. Introduction. 
Non-viral vectors engineered as nanoparticles or complexes are an attractive gene 
delivery method due to their safety, high gene carrying capacity and scalable mass 
production1,2. Unfortunately, non-viral vectors are in general much less efficient compared 
to viral alternatives. This has been attributed, amongst other reasons, to their inability to 
overcome extra- and intracellular barriers; and to poorly target the cell membrane for 
subsequent endocytosis-mediated internalization.  
In order for a delivery vector to efficiently transfect transgenes either in vitro or in vivo, 
nanoparticle formulations must first come into contact with and bind the cell membrane, 
rapidly enter the cell, in case of endosomal entrapment avoid lysosomal and cytosolic 
degradation and for plasmid (p)DNA-based therapeutics enter the cell nucleus to be 
transcribed3. There are ongoing efforts to design non-viral vectors capable of efficiently 
overcoming these limitations4. Slow vector accumulation and therefore low pDNA 
concentration on the cell membrane is a major barrier for most gene delivery methods, 
therefore any approach capable of accelerating the pDNA-vector interaction with the 
target cells could be hypothesized to result in enhanced gene delivery and transgene 
expression5,6. Furthermore, a method to promote vector accumulation that could be 
remotely controlled and localized would be the most desirable. All these requirements 
have led to a relatively new technology termed magnetofection7. This acronym (first 
mentioned in 20007) loosely refers to any magnetically guided or enhanced nucleic acid 
delivery, the most common approach involving the association of vectors (viral and non-
viral) with magnetic carriers, such as magnetic nanoparticles (MNPs). These accumulate 
on the cells by the application of magnetic field gradients. In the past years, 
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magnetofection has shown very promising results both in vivo and in vitro8–13. 
Additionally, magnetofection provides the opportunity not only to enhance targeted 
nucleic acid delivery in vivo, but it can also facilitate cell targeting of nanoparticle 
formulations to the area of interest in the context of cell therapy through MRI focussing or 
static magnets14–16. 
One of the most common non-viral vectors used for magnetofection is polyethylenimine 
(PEI)17–22. PEI is a branch polymer containing primary, secondary and tertiary amines 
capable of complexing pDNA and delivering it in vitro and in vivo. However, transfection 
efficiency of PEI as well as other non-viral vectors, remains low compared to their viral 
counterparts, and improvement in the field is still slow and limited. Additionally, despite 
being the current gold standard, PEI presents certain disadvantages such as elevated 
toxicity and lack of consistency and reproducibility in terms of transfection efficiency23. 
Previous work in our group has developed the glycosaminoglycan (GAG)-binding 
enhanced transduction (GET) system; based on combining the activities of peptide-cell 
membrane interaction with GAGs and cell penetrating peptides (CPPs). A second-
generation modified GET peptide, FGF2B-LK15-8R (FLR), has shown efficient gene 
delivery in vitro and in vivo with superior transfection efficiencies generating nanoparticles 
of GET-pDNA to current gold standard branched polymers or PEI24. We have exploited 
this technology in vivo for bone repair25 and lung gene delivery24; both based on delivery 
of transgenes expressed from pDNA. However, the system can also transfect mRNA and 
oligonucleotides, making it a generic vector for nucleic acid-nanoparticle-based delivery 
technologies26. The FGF2B-LK15-8R (FLR) peptide is formed of three domains: a 
fibroblast growth factor 2 (FGF2B) heparin-binding domain (TYRSRKYTSWYVALKR) 
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with high affinity for heparan sulphate proteoglycans present on the cell surface, which 
acts as a membrane docking domain27. LK15 (KLLKLLLKLLLKLLK) an amphipathic 
sequence able to complex DNA with endosomal escape activity28 and a cell penetrating 
peptide (CPP) 8R (RRRRRRRR) which further enhances  endocytosis26 (Figure 1A). 
FLR-pDNA nanocomplexes rapidly bind to cell membranes and are internalized; however 
they cannot be physically focused to transfect specific cells in vitro or tissues in vivo; with 
duration of cell exposure dictating absolute and local levels of gene transfection 
activity24,29.In this study, we focused on developing a FLR-DNA-MNP co-formulation 
complex for efficient magnetically-mediated gene delivery of pDNA. Understanding the 
advantages and limitations of magnetofection is key for the development of effective 
delivery systems and therefore we characterized complex binding, uptake and 
transfection activities dynamically under static magnetic fields. The cellular entry 
mechanism of FLR-DNA-MNP nanocomplexes in the presence or absence of a magnetic 
field was determined through the inhibition of specific uptake pathways. The predominant 
mechanism of uptake was dictated by the presence of the magnetic field; with caveolae 
mediated endocytosis playing a more dominant role under magnetic fields. Uptake 
kinetics, endosomolysis, extra- and intracellular pDNA degradation and confocal 
microscopy were also utilized to assess the combined effect of magnetic- and GET-
mediated gene delivery. We were able to demonstrate exceptional levels of faithfully 
localized gene expression with combination of our nanocomplex systems, which enabled 
more rapid (almost instantaneous, 5 second) cell membrane binding and subsequent 
uptake of FLR-DNA-MNPs when targeted with magnets in NIH3T3 cells. Use of such 
technologies will allow focused gene delivery to be translated for next-generation 
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regenerative and disease-targeting augmentation and editing approaches. Rapid and 
effective gene delivery systems such as GET magnetofection clearly demonstrate the 
significance of magnetic field application in the future of drug delivery using nanocomplex 
formulations. 
 
2. Materials and Methods.  
2.1. Physicochemical analysis. Nanomag®-D MNPs (Fe3O4 core; 250 nm; 09-02-252) 
were purchased from Micromod (Germany). The size and zeta potential of the bare, FLR 
or FLR-DNA functionalized MNPs were measured in water (distilled H2O) using Malvern 
Nanosizer Nano ZS.  
2.1.1. Dynamic light scattering (DLS). Measurements consisted of 3 repeats (12-15 
sub-runs per repeat) of the same sample to estimate the error in the measurements. The 
measurements were recorded at room temperature.  
2.1.2. Zeta potential. Measurements consisted of 3 repeats (12-15 sub-runs per repeat) 
of the same sample to estimate the error in the measurements. The measurements were 
recorded at room temperature. As zeta potential measurement was performed in an 
aqueous solution, the Smoluchowski approximation was used to calculate the zeta 
potentials from the measured electrophoretic motilities.  
2.2. Cell culture.  Unless otherwise specified, NIH3T3 cells were used in this study. 
NIH3T3 cells were chosen as a model to validate and characterize the FLR-DNA-MNP 
technology because of their consistency and robustness. All cell lines were cultured at 
37°C in 5 % CO2 in Dulbecco’s modified Eagle´s medium (DMEM; Sigma), supplemented 
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with 10 % (v/v) Fetal Calf Serum (FCS, Sigma), 4.5 g/L D-Glucose, 2 mM L-glutamine 
and 100 units/mL penicillin and 100 units/mL streptomycin (Invitrogen). All methods and 
reagents unless specified have been detailed previously24–26,29–31. 
2.3. Plasmids and purification.  Gaussia luciferase reporter (GLuc) was expressed by 
delivery of the pCMV-GLuc2 (termed pGLuc) DNA (expresses secreted luciferase from 
the copepod Gaussia Pinceps under the control of cytomegalovirus (CMV) promoter) 
(New England Biolabs; NEB). Enhanced Green fluorescent protein (GFP) was expressed 
by delivery of the pEGFP-C1 pDNA (expresses enhanced GFP under the control of CMV 
promoter) (Takada). pDNA was propagated in DH5α competent E. coli. and transformants 
selected for antibiotic resistance on LB agar plates. Individual colonies were picked and 
expanded to maxiprep volume with LB broth (with ampicillin 100μg/mL or kanamycin 
50μg/mL). Bacterial pellets were purified using Qiagen Plasmid Purification Maxi kit, 
following the manufacturer’s protocol. pDNA was diluted in nuclease free water (Sigma). 
Final pDNA concentration and purity were measured by Nanodrop (NanoDrop ND-1000, 
Labtech International). pDNA was aliquoted and stored at -20oC. 
2.4. Plasmid labelling. pGLuc DNA was labelled at a 1:1 ratio (v/w) of Label IT CX 
Rhodamine reagent to nucleic acid according to manufacturer’s specifications (Mirus). 
Briefly, 5μl of 10X Labelling Buffer A was mixed with 5μl of 1mg/mL pDNA and 5μl of 
Label IT CX Rhodamine Reagent in 35μl of nuclease (DNase, RNase)-free water. The 
mix was incubated for 1 hour at 37oC. Labelled pDNA was purified using a G50 Microspin 
Purification Column. Labelled pDNA (Rh-pDNA) was stored protected from the light at -
20oC. Unless otherwise specified, for in vitro studies the following formulation was used: 
1:3 of labelled pDNA diluted with unlabelled pDNA (w/w). 
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2.5. DNA complexation assays. In order to assess the interaction of FLR and pDNA we 
used YO-PRO-1TM Iodide assays (ThermoFisher Scientific). Briefly, for each individual 
repeat, 1μg of pDNA was diluted in 6μl of 10 mM HEPES buffer (pH 7.4). Similarly, 0.03μl 
of YO-PRO-1 (1mM) was diluted in 6μl of the same buffer. The pDNA solution was added 
dropwise to the YO-PRO-1 solution, and incubated for 5 hours at room temperature 
protected from light. These quantities were scaled-up proportional to the number of 
repeats per experiment, making up one stock solution of YO-PRO-1-DNA. The YO-PRO-
1-DNA solution was diluted to a final concentration of 10μg/mL in 10 mM HEPES buffer 
(pH 7.4). An increasing amount of peptide corresponding to the desired charge ratio 
between amine (NH2+) groups in the peptide and phosphate (PO3-) groups in pDNA (N/P) 
was added, followed by mixing and further incubation for 10 min (Table 1). Fluorescence 
intensity was measured at ex/em 480/509nm (Infinite® 200 PRO, Tecan). Experiments 
were performed in triplicate and results are expressed as percentage of fluorescence of 
YO-PRO-1-DNA against charge ratio (N/P). YO-PRO-1 only was used as blank. 
2.6. Magnetofection and transfection. Cells (4.2x105 NIH3T3 cells/cm2) were seeded 
on a 48 well plate format (unless otherwise specified) 24 hours before the treatment. Prior 
to transfection, medium in the wells was replaced. FLR-DNA-MNPs were formulated as 
described (Table 2). For magnetofection, cells were placed on top of individual magnets 
arranged in an array, and the plate fixed for the exposure duration (Magnet array 
schematic; Figure S1). After transfection/magnetofection, cells were washed three times 
with PBS or heparin (first wash 100 μg/mL in PBS, then two washes with PBS). PBS was 
replaced with growth media followed by further 24 hour incubation at 37°C in 5% CO2.  
Neodymium magnets, N52 10 mm diameter and 5 mm thickness (3.2kg pull, F645-N52-
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10), and N42 20mm diameter 5mm thickness (7.3kg pull, F205-4) were used for 
magnetofection of 48 wells and targeting a specific region in 6 well plates, respectively 
(First for Magnets, UK). 
2.7. Cell viability assays. Twenty-four hours after treatment, cells were trypsinized and 
diluted in Trypan Blue (1:1) for cell counting. Percentage of cell viability was calculated 
based on the total number of viable cells for each group compared to the untreated 
control. Half the trypsinized cells were plated again. Proliferation was measured as the 
cumulative number of viable cells every 24 hours for 7 days. 
2.8. Reporter gene expression. 
2.8.1 Luciferase activity. Gaussia Luciferase expression was measured using BioLux 
Gaussia Luciferase Assay Kit (New England Labs, UK). Briefly, 10μl of medium was 
collected from each transfection well and added onto a white 96-well plate (Corning, UK). 
50μl of Gaussia luciferase (GLuc) assay solution were added to each well, GLuc assay 
solution (1:100 dilution BioLux GLuc Substrate into BioLux GLuc Assay Buffer). 
Luminescence was measured using a luminometer (Infinite® 200 PRO, Tecan), 
integration time 500 ms. Untransfected and no pDNA GET-MNPs were employed in each 
experiment as negative transfection controls, and the basic GET-pDNA system26 (FLR-
DNA) was used as a positive control. 
2.8.1 GFP fluorescence. GFP-expressing cells were imaged by fluorescence (Leica DM 
IRB) and confocal (LSM880C, Zeiss, Germany) microscopy. GFP transfection efficiency 
(% positivity) and expression intensity was quantified by flow cytometry. 50,000-100,000 
total events were recorded per sample (Astrios EQ sorter, Beckman Coulter, US). 
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Untreated cells were used as control. For targeting within a single culture, cells were 
plated as a contiguous monolayer within wells of a 6 well plate (34.8 mm diameter, 9.5 
cm2 culture area) containing a sterile coverslip (Borosilicate Glass, 20 mm diameter, 3.1 
cm2 culture area). Coverslips were affixed to the centre of the culture surface with sterile 
vacuum grease, allowing them to be readily removed with forceps after seeding, exposure 
and washing. On transfection, targeting to the coverslip was achieved by placing the well 
on the array as previously described, a 20 mm diameter magnet aligning with the 
coverslip. After the incubation, the array was removed, and cells washed as described 
before with PBS or Heparin. The coverslip was removed to a fresh well with forceps, and 
targeted (IN region, 3.1 cm2) and untargeted (OUT region, 6.4 cm2) cells incubated as 
before analysis. 
2.9. Cellular Uptake Inhibition. NIH3T3 cells were exposed to one of the following 
conditions for 30 min prior to transfection: (1) incubated at 4oC (as opposed to 37oC), or 
(2) addition of 0.45 M of sucrose (Sigma, S9378)21,32, (3) 100 μM of 5(N-ethyl-N-isopropyl) 
amiloride (EIPA) (Sigma, A3085)33 and (4) 5 mM methyl-B-cyclodextrin (MBCD) (Sigma, 
C4555)34,35 in growth medium. Cells were transfected with FLR-DNA or FLR-DNA-MNPs 
(formulated with Rh-pDNA) and incubated for 1 hour with or without exposure to a 
magnetic field. Transfection was carried out at 4oC for inhibition at low temperature. All 
other transfections were carried out at 37oC. Control group was transfected at 37oC in 
normal growth medium without inhibitors. After one hour, cells were washed with PBS or 
heparin (100 μg/mL). Red fluorescence in the cells was quantified by flow cytometry. Each 
sample was run individually through a flow cytometer, 50,000-100,000 total events were 
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recorded per sample (Astrios EQ sorter, Beckman Coulter, US). Untreated cells were 
used as control. 
2.10. Cell extraction of transfected pDNA. After transfection/magnetofection, cells were 
washed with PBS. Cells were then incubated in normal growth medium at 37oC 5% CO2 
until collection: immediately after transfection (0 min), 10 min, 25 min, 55 min and 24 
hours (1440 min) post transfection. Briefly, cells were trypsinized for 3 min at 37oC, 5% 
CO2 after which the trypsin was neutralized with pre-warmed medium. Cells were pelleted 
and resuspended in 50μl Hirt buffer (10mM EDTA, pH 7.5, and 0.6% SDS). This was 
incubated at 4oC for 8 hours after which they were stored at -20oC until DNA 
extraction/purification. For pDNA purification, QIAprep Spin Miniprep kit was used 
according to manufacturer’s specifications (QIAGEN, Cat: 27106) with the extract added 
to 500 μl PB buffer. DH5α competent E. coli (40 μl) were added to purified DNA (2.5 μl) 
and incubated for 30 min on ice. Cells were then heat shocked for 45 seconds in 42oC 
water bath and replaced to ice for 5 min. Cells were then incubated in pre-warmed SOC 
recovery medium for 1 hour at 37oC, shaking at 225 rpm. After incubation 50μl of each 
transformation were spread on a selective LB agar plate (100μg/mL ampicillin). Plates 
were then incubated overnight at 37oC. Colonies were counted the following day, and 
compared to an extraction control (pDNA quantity transfected, added to a cell pellet and 
extracted). 
2.11. Confocal imaging. NIH3T3 cells were seeded on sterilized glass coverslips 
(Borosilicate Glass, 13 mm diameter, VWR). Cells were transfected with FLR-DNA or 
FLR-DNA-MNPs (formulated with Rh-pDNA) in OptiMEM formulated as previously 
described. After 30 min, 1 hour and 24 hours of incubation cells were fixed in 3.7% 
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paraformaldehyde and permeabilized using triton X-100 for 15 min then washed in PBS. 
Actin cytoskeleton was visualised by staining with Alexa Fluor 488 Phalloidin (Thermo, 
A12379). The coverslips were washed and sealed onto slides with DAPI containing 
Fluoroshield mounting medium (Sigma Aldrich, UK). Cells were imaged using a LSM880C 
Confocal Microscope (Zeiss, Germany). A 63x immersion objective lens was used with a 
488 nm laser used for Hoechst and Phalloidin stained cytoskeleton and a 561 nm Diode-
pumped solid-state (DPSS) laser for Rhodamine labelled (Rh-) pDNA. Images were 
captured using ZEN software (Zeiss, Germany). Three-dimensional image stacks were 
recorded by sequential acquisition of optical sections along the z-axis with steps of 0.33-
0.37 µm. The acquired digital images were merged and processed by using ImageJ 
version 4. 
2.12. Iron quantification by Inductively Coupled Plasma Mass spectrophotometry 
(ICP-MS). MNPs were delivered as described above. After incubation overnight, the 
supernatant was removed and cells were washed twice with PBS. Cells were trypsinized 
and lysed in HCl 6M, HNO3 (65 %) for 2 hours at room temperature for the degradation 
of the particles in order to release the Fe content. Samples were then diluted in water in 
order to achieve a final acid concentration of less than 2% (w/v). A calibration curve was 
also produced at MNPs concentrations up to 50 µg/mL, to account for possible matrix 
effects. Diluted solutions were analyzed by ICP-MS (Thermo-Fisher Scientific iCAP-Q; 
ThermoFisher Scientific, Bremen, Germany).  Elemental analysis of diluted solutions was 
undertaken by ICP-MS (Thermo-Fisher Scientific iCAP-Q and iCAP-TQ; Thermo Fisher 
Scientific, Bremen, Germany). Samples were introduced (flow rate 1.2 mL/min) from an 
autosampler (Cetac ASX-520) incorporating an ASXpress™ rapid uptake module through 
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a perfluoroalkoxy Microflow PFA-ST nebulizer (Thermo Fisher Scientific, Bremen, 
Germany).  Sample processing was undertaken using Qtegra™ software (Thermo-Fisher 
Scientific) utilizing external cross-calibration between pulse-counting and analogue 
detector modes when required.  Internal standards were introduced to the sample stream 
on a separate line via the ASXpress unit and included Ge (10 µg/L), Rh (10 µg/L) and Ir 
(5 µg/L) in 2% trace analysis grade (Fisher Scientific, UK) HNO3.  Fe External calibration 
standard (Claritas-PPT grade CLMS-2 from SPEX Certiprep Inc., Metuchen, NJ, USA), 
in the range 0 – 100 µg/L (0, 20, 40, 100 µg/L) was employed, with phosphorus, boron 
and Sulphur calibration by in-house standard solutions (KH2PO4, K2SO4 and H3BO3). A 
collision-cell (Q cell) using He with kinetic energy discrimination (He-cell) to remove 
polyatomic interferences was used to measure Fe. Sample processing was undertaken 
using Qtegra™ software (Thermo-Fisher Scientific). Results were reported back in ppb 
(µg/L). Iron association per cell was calculated based on the doubling times of the 
respective cell lines to estimate total number of cells.  
2.13. Hemolysis. To assess the hemolytic activity of FLR-DNA-MNPs complex (as a 
proxy for endosomal membrane rupturing activity), freshly isolated human erythrocytes 
(6 x 106 erythrocytes/mL) were exposed to 0.5 µM of FLR. FLR-DNA was formulated at 
an N/P ratio 6. 5µg of MNPs/µg of DNA was added to form the FLR-DNA-MNPs. 
Hemolysis experiments were performed in PBS for 30 min at physiological pH (pH 7.5) 
and late endosome pH (pH 5). After incubation, samples were centrifuged at 5000xg for 
5 min. The supernatant was collected and hemoglobin content was analyzed by 
spectrophotometry at 544 nm (Infinite® 200 PRO, TECAN). PBS was used as control. 
Results are expressed as percentage lysis taking Triton-X 100 as complete lysis (100%).   
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2.14. Statistical analysis. For in vitro studies n represents the number of biological 
replicates. Technical replicates refer to experiments carried out with different passage 
cells but identical experimental conditions. Data were presented as mean ± standard 
deviation (s.d.) and analyzed by Prism statistical analysis software (GraphPad v. 7.03). 
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3. Results & Discussion 
3.1. Co-complexation FLR peptide, pDNA and MNPs for GET Magnetofection. In 
order to develop a targetable GET peptide transfection system we generated an FLR-
MNP based gene delivery nanocomplex following a step by step formulation process6 
(Figure 1B). The optimal amount of FLR needed to fully complex DNA was initially 
confirmed using a YO-PRO-1 dye fluorescent-based assay for DNA complexation. Briefly, 
YO-PRO-1 (carbocyanine) becomes fluorescent through DNA binding via its positive side 
chain. The amount of fluorescence emitted is proportional to the amount of free non-
complexed DNA. When DNA is complexed or interacts with other molecules such as 
cationic FLR peptides, the YO-PRO-1-DNA interaction becomes unstable, quenching 
fluorescence proportionally to the amount of DNA complexed. We exploited this assay to 
study optimal negative/positive (N/P) ratio for DNA complexation24. Increasing 
concentrations of FLR were added to defined amounts of YO-PRO-1-labelled pDNA, 
confirming that as FLR concentration increased, YO-PRO-1-DNA fluorescence 
decreased; indicating direct interaction of FLR with pDNA (Figure 1C). Total pDNA 
complexation occurred at N/P ratios of 4 (7.4 ± 5.6 % of fluorescence left) or above. We 
therefore focused on formulations containing a minimum FLR concentration to allow full 
complexation of pDNA, that being N/P ratio of 4 or more. 
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Dextran-coated MNPs are approved by the Food and Drug Administration (FDA) for their 
use in vivo and are currently being optimised for multiple applications in biomedicine16,36–
38. We have previously shown that positive GET peptides complex to the negatively 
charged dextran coating of Nanomag-D MNPs (MicroMod) and enhance the cell uptake 
of the MNPs26,37,39. In our previous studies39, we focused on the characterization of the 
complexation of GET peptide and MNPs, establishing the minimum amount of GET 
peptide required in order to enhance cellular uptake of MNPs, as well as the concentration 
of GET at which MNPs would be saturated. We found that the optimal concentration of 
GET for MNPs delivery (4 nmol of GET per mg of MNPs) was significantly inferior to the 
saturation maximum (40 nmol for GET per mg of MNPs). It was therefore key to assess 
the co-complexation of all 3 components and the amounts of FLR needed to both interact 
with MNPs, and fully complex pDNA before testing transfection ability of the nanocomplex 
formulations. 
To confirm if pDNA can indeed be incorporated into FLR:MNP nanocomplexes, 
rhodamine-labelled pDNA (Rh-pDNA) were used for complexation at increasing 
concentrations of MNPs and at N/P ratio 6. After complex assembly, MNPs were 
separated using a static magnetic field and unbound Rh-pDNA was measured in the 
supernatant using fluorimetry to define percentage absorption. As the concentration of 
MNPs increased, the percentage of DNA adsorbed onto the particles increased 
progressively towards a plateau, suggesting an adsorption mechanism of the FLR-Rh-
DNA nanoparticles onto the MNPs surface (Figure 1D). 
In order to assess whether the pDNA associated with FLR:MNP complexes remained 
directly associated with FLR after incorporation we again exploited the YO-PRO-1 assay. 
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YO-PRO1-labelled pDNA was incubated with FLR at an N/P ratio of 6 and then with 
increasing amounts of MNPs (5, 10, 25 and 50 µg MNPs/ 1µg pDNA) (Figure 1E). The 
percentage of complexed pDNA was calculated as a function of the loss in fluorescence 
in solution compared to YO-PRO-1-labelled pDNA only controls. There is no significant 
difference in pDNA complexation in the presence of any concentration of MNPs tested. 
This data indicates that binding of the FLR-pDNA complexes to the MNPs does not disturb 
FLR-DNA interactions, or at least, not sufficiently to dequench YO-PRO-1 and allow its 
productive binding to pDNA.   
3.2. Defined monodispersed FLR-DNA-MNP nanocomplexes. After confirmation that 
FLR peptide, pDNA and MNPs can form co-complexes we assessed their physical 
characteristics, using dynamic light scattering (DLS) and zeta potential analyses (Table 
3). As previously confirmed MNPs alone are negatively charged due to their dextran 
coating. In the presence of FLR, all MNP nanocomplexes are positively charged, 
indicating the disposition of FLR on the outer layer of MNPs. In contrast, when MNPs 
were incubated with pDNA only, particle charge became significantly more negative 
compared to MNPs alone (-31.6 ± 0.8 mV and -20.7 ± 0.5 mV respectively) suggesting 
that pDNA even though negatively charged can interact with MNPs. Particle size 
measurement by DLS suggests MNP complexes are mostly in the monodisperse range 
after functionalization with FLR and DNA-FLR (Table 3)40. FLR-DNA-MNPs (244.7 ± 8.5 
nm) are larger than MNPs alone and FLR-MNPs (225.1 ± 4.4 nm and 228 ± 4.6 nm 
respectively), and comparable to MNPs-DNA (239.1 ± 3.9 nm). This ~20 nm increase in 
diameter could be attributed to pDNA absorption to the MNPs. FLR-DNA complexes are 
124.6 ± 2.9 nm, suggesting the size of FLR-DNA-MNPs did not represent the coalescing 
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of these sized FLR-DNA complexes with MNPs. Based on these findings and the 
previously reported adsorption of pDNA onto the MNPs, as well as the stable 
complexation of pDNA throughout the adsorption process; we hypothesize that upon 
encountering MNPs, FLR-DNA nanocomplexes interact with surface functional groups of 
MNPs and rearrange seeking the most stable conformation41. The positive zeta potential 
of FLR-DNA-MNP complexes suggests that positively charged FLR is arranged in the 
outer layer of the particle shielding the negative charge provided by absorbed pDNA and 
the MNP dextran-coating. We therefore confirmed the successful formulation of FLR-
DNA-MNP nanocomplexes for further testing. 
3.3. FLR-DNA-MNP nanocomplexes retain high transfection activity. We next 
assessed if the inclusion of MNPs in FLR-DNA nanocomplexes was compatible with cell 
uptake and delivery. We undertook a series of reporter transfection experiments in 
NIH3T3 cells transfected with a secreted Gaussia Luciferase (GLuc)-encoding plasmid 
(pCMV-GLuc2; termed pGLuc) comparing complexes with and without MNP inclusion. 
We exposed cells for 24 hours using a FLR-DNA formulation at N/P 4, 5 and 6 and 
increasing concentrations of co-complexation MNPs (5, 10, 25 and 50 µg MNPs/µg 
pDNA).  
Cells transfected with FLR-DNA nanocomplexes alone at N/P ratios 4, 5 and 6 were used 
as controls (0 µg MNPs/µg of DNA) and to confirm any inhibitory effect of MNPs on 
transfection. Gene transfer efficiency was measured by GLuc protein expression secreted 
into the media by luminometry (Figure 1F). N/P ratio 6 showed significantly enhanced 
protein expression overall when compared with lower ratios. There were no significant 
differences in transfection efficiency between the MNP-free control (0 µg MNPs/µg of 
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DNA) and the highest doses of MNPs (25 and 50 µg MNPs/µg of DNA) when comparing 
transfection at the same N/P, suggesting  that transfection efficiency was not significantly 
affected with the inclusion of MNPs, even at the highest amounts tested. MNPs are 
therefore compatible with cell uptake and transfection activity. These findings further 
corroborate our previous hypothesis that FLR-pDNA nanocomplexes are not destabilised 
upon adsorption onto the MNPs (Figure 1E). The GET peptide system not only allows 
coupling and condensation of the pDNA cargo with MNPs, but also enhances transfection 
efficiency. We have extensively shown that without the DNA cargo, GET-conjugated 
nanocomplexes have significantly improved the speed and loading of MNPs into cells26, 
which also we now show for the co-delivery of pDNA in the GET-MNP nanocomplex. 
 
3.4. GET Magnetofection significantly enhances transfection speed. In order to 
determine the effect of a magnetic field on FLR-DNA-MNP co-complex gene delivery, we 
assessed for overall transfection efficiency and transfection speed in the presence or 
absence of a magnetic field19,22,42,43. 
Previous data suggested that 5 and 10 µg MNPs/µg of DNA were the most efficient for 
magnetofection at N/P 6. Optimal concentration of MNPs for magnetofection during short 
incubation periods (1 hour) was established at 5µg of MNPs per µg of pDNA (µg/µg 
pDNA) (Figure S2). Cells were transfected with pGLuc for short or longer durations (1 
hour or 24 hours, respectively) with and without an external magnetic field (Figure 2A) 
using MNPs-DNA and FLR-DNA nanocomplexes as controls. FLR-DNA-MNP 
nanocomplex transfection was significantly enhanced (almost 2-fold) by the presence of 
a magnetic field during 1 hour transfection (2.09 ± 0.45 x 107 RLU with a magnet 
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compared to 1.13 ± 0.6 x 107 RLU without a magnet). Interestingly, in one hour FLR-DNA-
MNPs in the absence of an external magnetic field induced similar levels of transfection 
as FLR-DNA (0.80 ± 0.76 x 107 RLU), once again suggesting MNPs did not hamper the 
gene transfer process. After a 24-hour exposure, cells transfected with both FLR-DNA 
and FLR-DNA-MNP nanocomplexes showed comparable levels of protein expression 
independent of the magnetic field. Transgene expression after 24 hours was comparable 
to that of FLR-DNA-MNPs in 1 hour under a magnetic field. 
These data confirm that the FLR-DNA-MNP co-complex formulation could induce 
comparable protein expression to its non-magnetic counterpart FLR-DNA in the absence 
of a magnetic field. Importantly, under the influence of a magnetic field FLR-DNA-MNP 
nanocomplexes were able to achieve maximal transfection expression after only 1-hour 
magnetofection.  
3.5. GET Magnetofection does not affect cell viability. The effect of magnetofection 
on viability and growth of NIH3T3 cells was assessed using a Trypan Blue-based assay 
(Figure 2 B and C respectively) and metabolic assays (PrestoBlue, data not shown). Cells 
were transfected for 1 hour with pGLuc incorporated within FLR-DNA and FLR-DNA-MNP 
nanocomplexes with or without an external magnetic field. We tested 1 hour 
magnetofection as this generated the same transfection levels of an overnight exposure 
with FLR-DNA complexes. Cell proliferation and viability were assessed 24 hours post-
transfection (day 1) and every 24 hours for 7 days. There were no significant differences 
in cell viability or proliferation across all treatment groups compared to untreated controls 
as determined by the Trypan blue dye exclusion assay (Figure 2C) and metabolic 
assessments (data not shown). Metabolic assessment post-delivery (immediately and 
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after 24h) showed that there was no statistically significant difference after uptake, with 
or without magnetic targeting.  These data indicate that regardless of the rapid 
accumulation of nanocomplexes on the cell membranes, and enhanced uptake mediated 
by magnetofection, the doses of pDNA, FLR peptide and MNPs were fully cytocompatible. 
We compared the magnetically targeted GET-MNP system, with or without magnets to 
PEI44. PEI was slow to transfect, and yielded ~3-fold lower transfection levels in DC2.4 
(dendritic cells) and ~1.5-fold lower in HeLa cells (data not shown). GET-MNP 
transfection with 30min magnetic targeting yielded higher levels of reporter expression 
than the full transfection exposure (overnight) of the PEI-based systems (data not shown). 
Furthermore, there was no statistically significant effect on viability (trypan blue dye 
exclusion) or metabolism (Presto Blue) with any of the GET-MNPs variables, but PEI even 
at short exposures (>1h) showed some effect on viability and metabolism, with full 
exposures showing a ~10% increase in dead cells (trypan blue) and ~20% reduction in 
cell metabolism (PrestoBlue) (data not shown). 
 
3.6. Significant GET Magnetofection with 5 second exposures. As we have previously 
shown, FLR-DNA nanocomplexes transfect cells rapidly in comparison to some other 
systems24. As a short 1 hour exposure still generated significant transfection irrelevant of 
magnetic targeting, we repeated experiments with ever shorter incubations times with and 
without magnetic field. Our goal was to gain further understanding of transfection kinetics 
mediated by FLR-DNA and FLR-DNA-MNP nanocomplexes with and without an external 
magnetic field. NIH3T3 cells were transfected for increasing amounts of time (from 5 min 
to 60 min). We assessed transfection kinetics by reporter gene expression (GLuc); FLR-
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DNA-MNP nanocomplexes delivered under an external magnetic field were able to 
generate significant levels of reporter gene expression after just 5 min (1.13 ± 0.27 x 107 
RLU), which was comparable to gene expression mediated by FLR-DNA or FLR-DNA-
MNPs after 1 hour incubation (Figure 3A). Importantly, we also conducted shortened 
exposure times to assess how effective partial targeting was on transgene expression. 
Our shortest exposure tested was 5 seconds, which was the minimum that was 
technically feasible and reproducible. In 5 seconds most nanocomplexes were not 
focused onto the cell monolayer (only 8.25 ± 1.87 % was cell associated by ICP-MS of 
iron) but this still produced significant (although variable) transfection levels (2.14 ± 1.31 
x 105 RLU). This was achieved with the FLR-DNA-MNP co-complex and static magnet 
combination. Without magnetic targeting, we observed very low levels of MNP cell 
association and reporter expression in 5 seconds (~0.82 ± 0.37 % by ICP-MS of iron, 1.62 
± 1.31 x 103 RLU).  One minute exposures were more reproducible and technically easy 
to standardize. This was sufficient to focus significant amounts of the FLR-DNA-MNP 
nanocomplexes to cell monolayers (43.47 ± 8.65 % by ICP-MS) and yielded similar 
transfection levels to that of 5 min exposure (65.76 ± 10.03 % by ICP-MS) under magnetic 
field (0.41 ± 0.76 x 107 versus 0.80 ± 0.76 x 107 RLU, respectively). Therefore short and 
incomplete targeting of GET magnetofection nanocomplexes can yield significant 
transfection levels in seconds. 
 
3.7. pDNA is rapidly cell membrane-associated and uptaken with GET 
Magnetofection. We next assessed the location of the pDNA cargo under these 
conditions, defining percentage of pDNA labelled cells (using labelled Rhodamine (Rh)-
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pDNA) and also the amount of pDNA delivered per cell (intensity mean). Initially it was 
important to assess the effect of Rh-labelling of pDNA on its ability to transfect, be a 
transcriptional template for the reporter, and confirm lack of toxicity (Figure S3). Delivery 
of Rh-pDNA pGLuc did not affect cell metabolic activity and performed similarly to 
unlabelled pDNA in NIH3T3 cells when transfected with FLR nanocomplexes. Next, Rh-
pDNA was employed to quantify pDNA association with cells using FLR-DNA and FLR-
DNA-MNPs with/without a magnet at increasing time points. After delivery, cells were 
washed with PBS to remove any unbound complexes and trypsinized to collect cells for 
flow cytometry. 
Flow cytometry quantification of the percentage of Rhodamine-positive (Rh+) cells 
confirmed the association of Rh-pDNA to the cell as early as 5 min (70 ± 12% of positive 
cells with FLR-DNA-MNPs-magnet compared with 4 ± 2% and 6.4 ± 2% for FLR-DNA 
and FLR-DNA-MNPs respectively) (Figure 3B). Rh-pDNA association over time followed 
two different trends when FLR-DNA-MNPs were delivered with or without a magnetic 
field. The percentage of Rh+ cells remained almost constant over 60 min (at around 80%) 
when Rh-pDNA was delivered in FLR-DNA-MNPs in the presence of magnetic field, 
suggesting a saturation of MNP cell association45. On the other hand, in the absence of 
a magnetic field Rh-pDNA association increased progressively overtime (6.4 ± 2% and 
39.3 ± 7.7%, at 5 min and 60 min, respectively). Rh-pDNA association when delivered 
with FLR showed a similar pattern overtime than FLR-DNA-MNP nanocomplexes in the 
absence of a magnetic field.  
Interestingly, the mean fluorescent intensity per cell remained constant or minimally 
increased over time with longer incubations (Figure 3C). This data suggests that similar 
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amount of pDNA is either membrane bound or uptaken in the same experimental 
conditions, however longer exposure times increase the overall percentage of labelled 
cells (Figure 3B). The application of an external magnetic field on FLR-DNA-MNP 
nanocomplexes allows for rapid concentration of pDNA on cells; in the absence of any 
magnetic forces the FLR-DNA-MNP nanocomplexes and non-magnetic FLR-DNA 
nanocomplexes progressively accumulate onto cell membranes over time.  
We next assessed MNP uptake using inductively coupled plasma mass spectroscopy 
(ICP-MS). NIH3T3 cells were incubated with FLR-DNA-MNP nanocomplexes for 
increasing amounts of time (5, 15, 30 and 60 min) with and without an external magnetic 
field. The amount of iron per cell was quantified 24 hours post-delivery by ICP-MS. 
Significantly more iron was associated in the cells in the presence of a magnetic field 
(Figure 3D). Importantly, iron content progressively increased with prolonged incubation 
times when FLR-DNA-MNP nanocomplexes were delivered in the presence of a magnetic 
field.  
It is important to note that despite the accuracy of the methods used to determine kinetics 
of transfection and particle internalization, they potentially struggle to differentiate bound 
nanoparticles from internalized complexes, providing inaccurate results46.  As one of the 
aims of this study was to confirm uptake mechanism, it was therefore important for us to 
technically distinguish between internalization and cell membrane association of 
nanocomplexes. In order to achieve this, cells were washed with either PBS as before – 
defined as cell associated (removing unbound or loosely bound nanocomplexes) or 
Heparin, known to destabilize the FLR-DNA interaction, and preventing gene transfer if 
nanocomplexes were not internalized – defined as cell internalized26. Destabilization of 
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the FLR-DNA complex in the presence of heparin was confirmed by YO-PRO-1 assay 
(Figure S4). Transfection efficiency and Rh-pDNA and MNPs internalization were 
assessed at 5, 15, 30 and 60 min by including an additional step of heparin wash after 
incubation (Figure S5-S7). Overall, values of transfection efficiency, Rh-pDNA uptake and 
iron internalization were lower after the cells were washed with heparin, suggesting that 
a significant fraction of the complexes associated with the cells (up to 60 min) are cell 
bound but not completely internalized with short incubation periods. However, despite the 
lack of internalization of both pDNA and MNPs after short incubation periods, in most 
cases, transfection with FLR-DNA-MNP nanocomplexes in the presence of a magnetic 
field is still significantly better than the other treatments. 
Taken together these studies suggest that even limited interaction of FLR-DNA-MNP 
nanocomplexes with cells is sufficient to generate significant magnetofection (and 
delivery of nanocomplexes constituents; pDNA and MNPs). Furthermore, targeted 
loading of cell membranes was the most important facet for rapid gene delivery using our 
system. 
 
3.8. Rapid regional targeting of transgene expression with GET Magnetofection. 
Since we confirmed significant enhancement of FLR-DNA-MNP nanocomplexes 
transfection efficiency under a magnetic field, we next assessed if an external static field 
could target transfection to specific regions of a cell monolayer in culture. For these 
experiments we transfected a pDNA that expresses enhanced GFP (pEGFP-CI) allowing 
measurement of transfection efficiency and levels at a cell autonomous level. GFP 
transfection mediated by FLR-DNA-MNP nanocomplexes with and without magnetic field 
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aligned well with pGLuc transfection (Figure 4). Exposures of 15 min to FLR-DNA-MNP 
nanocomplexes yielded enhanced transfection with a magnetic field by microscopy (38.9 
± 10.4% and 4.5 ± 2.3%, with and without magnet, respectively) (Figure 4Ai). When 
transfection efficiency was assessed by expression of GFP protein, we found that 1 hour 
transfection of FLR-DNA-MNPs in the presence of a magnet (48.0 ± 5.9%) was 
comparable to a 24 hour exposure of FLR-DNA nanocomplexes (56.9 ± 9.1%) (Figure 
4Aii).  
We next aimed to target specific cells in the same culture. To achieve this we developed 
an assay in which an interrupted monolayer can be seeded in culture, transfected and a 
specific region removed with the monolayer still intact; allowing more complete 
characterisation to transfection efficiency such as flow cytometry. This involved 
temporarily affixing a coverslip (20 mm diameter) to the middle of a 6 well plate with 
vacuum grease, allowing it to be readily removed with forceps after exposure and washing 
(Figure 4Bi). Magnetic-focusing of FLR-DNA-MNP nanocomplexes to cells generated 
significant transfection efficiency within magnetic field area by microscopy (Figure 4Bii) 
and quantitatively assessed with flow cytometry (IN region; 66.8 ± 8.3%), and prevented 
transfection of cells outside of the targeted area (OUT region, 0.6 ± 0.3%) (two-orders of 
magnitude increase in targeting), when compared to without magnetic field (4.3 ± 1.4%) 
(Figure 4Biii). This represented a 111-fold enrichment in transfection of the targeted area, 
and a reduction in background transfection without targeting of 7.2-fold. The accuracy of 
this targeting enhancing target and minimising off-targeting of pDNA could have 
implications when improving efficacy and safety of gene therapy strategies using 
nanocomplexes. 
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3.9. GET Magnetofection occurs via multiple endocytotic pathways. Most non-viral 
nanocomplex vectors are hydrophilic, which greatly inhibits their ability to passively 
traverse the hydrophobic cell membrane. Therefore, these systems require active, energy 
dependent endocytosis processes to cross the cell membrane. There is some evidence 
of lipoplex mediated pDNA delivery through fusion with the cell membrane and direct 
release to the cytoplasm but there is no confirmation that this is the case for cationic 
peptides/polymers such as our system47–50. The most widely researched endocytic 
pathways are clathrin or caveolae mediated endocytosis and macropinocytosis34.  GET 
mediated gene delivery has been previously associated with the macropinocytotic uptake 
pathway as vesicular-sequestered cargoes delivered with GET appear to have longer 
half-lives than would be expected. However it is likely that changes in cargo size, charge 
and payload could change the mode of uptake of any system26.  
It was important to confirm if rapid accumulation of FLR-DNA-MNP nanocomplexes on 
the cell membrane mediated by a magnetic field had an effect on the uptake mechanism. 
We conducted a series of experiments using labelled pDNA (Rh-pDNA) to quantify pDNA 
uptake. These compared FLR-DNA and FLR-DNA-MNP nanocomplexes with/without a 
magnet in culture conditions, aiming to inhibit uptake through endocytosis: low 
temperature (4oC) which rigidifies the cell membrane affecting both passive and active 
uptake21, hypertonic conditions (employing sucrose) to hinder clathrin lattice formation32, 
methyl-B-cyclodextrin (MBCD) to repress caveolae mediated endocytosis through 
complexation of cholesterol35 and amiloride, an inhibitor of Na+/H+ exchange required for 
macropinocytosis51. The experimental conditions including effective concentrations and 
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treatment times of low temperature (4oC), MBCD and amiloride had been previously 
validated26. Similarly, previous literature reported that treatment of NIH3T3 cells with 
MBCD (0-5 mM) or amiloride (0-5 mM) does not affect cell viability51.  
We dissected the effect of these inhibitory conditions on MNP cell association (by 
removing lightly bound complexes with PBS) and on particle uptake (by disrupting non-
internalized complexes with heparin). Interestingly, only hypertonic medium (containing 
high sucrose) which is known to disrupt clathrin lattices, significantly decreased overall 
pDNA cell association for FLR-DNA and FLR-DNA-MNP nanocomplexes with or without 
magnets (Figure 5A). However, all inhibitors significantly decreased pDNA internalization 
of the nanocomplexes (Figure 5B). FLR-DNA and FLR-DNA-MNPs without a magnet 
showed similar pDNA internalization patterns in response to the different inhibitors. Low 
temperature (4oC) known to rigidify cell membranes and hypertonic medium had the most 
significant effect on pDNA internalization, suggesting a heavy contribution of clathrin 
mediated endocytosis in the uptake process. Clathrin mediated uptake of similar size 
particles and magnetofection complexes has been previously reported in the 
literature21,34,43.  
Interestingly, when FLR-DNA-MNP nanocomplexes were delivered with a magnetic field, 
MBCD, which inhibits caveolae-mediated endocytosis, had a greater effect on pDNA 
internalization than sucrose, which inhibits clathrin lattice formation (Figure 5B). One of 
the hypothesis that could explain this change in uptake mechanism in the presence of 
magnetic field is based on previous observations reported in the literature that suggest 
that high concentrations of nanocomplexes on the cell membrane could saturate binding 
sites specific to a particular uptake mechanism52–54. We have previously demonstrated 
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that in the presence of a magnetic field FLR-DNA-MNPs are rapidly attracted towards the 
cell surface, increasing pDNA concentration on the cell membrane (Figure 3C). We 
hypothesized that the saturation of FLR-specific endocytotic pathways (previously 
suggested as macropinocytosis for mechanism of GET-mediated cargo uptake), triggers 
rerouting towards different endocytic internalization pathways, such as caveolae-
mediated endocytosis. Alternatively, aggregation of the MNPs in the presence of a 
magnetic field could explain the difference in the uptake mechanisms. Previous studies 
focusing on examining the direct effects of aggregation on magnetofection are limited, 
however, most seem to attribute particle aggregation to the medium composition (i.e. 
FBS) over the presence of a magnetic field45,55, which would not account for the 
differences observed in the presence of a magnetic field. 
It is important to note that FLR-DNA and FLR-DNA-MNP nanocomplexes in the absence 
of a magnetic field showed comparable uptake mechanisms. These results are in 
agreement with transfection data that shows both transgene expression and pDNA 
uptake profiles over time were similar for these complexes, reinforcing the hypothesis that 
the incorporation of FLR-DNA into MNP nanocomplexes does not prevent efficient gene 
delivery mediated by FLR and the mechanism of uptake is similar45,55,56.  
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3.10. FLR peptide mediates membrane rupturing endosomal escape in GET 
Magnetofection. We next aimed to understand how magnetofected nanocomplexes 
successfully navigate to the cell nucleus. After being internalized, endocytosed pDNA 
must be efficiently released into the cytosol and access the nucleus in order to transcribe 
the delivered pDNA encoded transgene. Endosomal membrane rupturing activity of FLR-
DNA, FLR-MNP and FLR-DNA-MNP nanocomplexes was assessed through hemolysis 
assay, in which erythrocyte membranes serve as a surrogate for the lipid bilayer 
membrane in endo-lysosomal vesicles57–60. 
Membrane disruption activity was assessed at physiological pH (pH 7.5) and late 
endosome/lysosome pH (pH 5). Hemolytic activity was calculated as a percentage of total 
hemolysis mediated by detergent Triton-X 100 (Figure S8). There were not significant 
differences between the hemolytic activity of FLR-DNA and FLR-DNA-MNP 
nanocomplexes independent of the pH (58.8 ± 14.8% and 48.7 ± 12.3% respectively at 
pH 7.5 and 53.8 ± 27.8% and 44.8 ± 20.8% respectively at pH 5). MNPs alone did not 
show any significant membrane rupturing activity. These results suggest that any 
endosomal escape activity, triggered by the complex, would be mostly mediated by the 
FLR peptide. Additionally, FLR membrane disruptive activity is pH independent, which is 
consistent with the lack of carboxylic side chains on FLR molecule, which are known to 
mediate pH-dependant endosomal disruptive activity57. The membrane disruptive activity 
of FLR could then potentially be explained by physical interaction between the peptide 
and the lipid bilayer, similar to that previously reported for similar peptides61. Furthermore, 
in this assay, membrane disruptive activity of FLR decreases in the presence of serum 
and drops down to approximately ~20% (19 ± 12.6 % hemolysis) at 10% FCS (in vitro 
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experimental conditions) (Figure S9). This would suggest that FLR should not significantly 
affect the cell plasma membrane integrity during transfection as observed indirectly in our 
cell viability and proliferation analyses. 
It is important to note that this hemolysis assay only assesses membrane rupturing 
activity due to chemical interactions with the cell membrane, but it does not account for 
endosome swelling or physical alterations of the loaded endosome. Additionally, this 
assay has been performed in PBS or FCS, which do not represent the intracellular 
environment (i.e. cytosol or endosome composition). Finally, in this assay, erythrocytes 
were used as a surrogate for endosomal membranes, however, the lipid content and 
exact composition of the endosomal membranes varies between cells. Isolation and 
analysis of the internal structure of FLR-DNA-MNP nanocomplex loaded endosomes may 
provide more understanding of endosomal membrane composition and how they escape 
efficiently into the cytosol59,62. Additional endosomal escape assays involving dye leakage 
or fluorescent fusion proteins would provide more information on the exact mechanism 
underlying pDNA translocation into the cytoplasm63,64. 
 
3.11. GET Magnetofected pDNA retains integrity when internalized. To evaluate the 
ability of FLR-MNP nanocomplex vectors and magnetofection conditions to deliver fully 
intact pDNA inside the cells as well as its stability post-transfection, pGLuc pDNA was 
delivered with FLR-DNA and FLR-DNA-MNP nanocomplexes with and without a magnet 
for 5 min. Extrachromosomal DNA, and therefore pDNA, was isolated and quantified by 
bacterial transformation efficiency (a maker for un-nicked, intact pDNA) at different time 
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points post-delivery65. Percentage of cell bound pDNA was calculated compared to total 
amount of pDNA delivered (Figure S10).   
A significantly higher percentage of intact pDNA was associated with NIH3T3 cells when 
delivered with FLR-DNA-MNPs in a magnetic field (36.1± 6.3 %) compared to FLR-DNA 
and FLR-DNA-MNPs in the absence of a magnetic field (1.3± 0.3 % and 1.9± 0.3 %, 
respectively) after 10 min incubation. The percentage of cell bound pDNA remained 
relatively constant during the first 60 min and decreased significantly up to 24 hours post-
delivery. Interestingly, the percentage of pDNA degraded over 24 hours was comparable 
in all transfection groups (the final percentage of intact pDNA after 24 hours was 
approximately 10% of the DNA present immediately post-delivery). Since all 
nanocomplex formulations were taken up through endocytotic pathways, degradation is 
most likely to be driven by enzymes present lysosomal compartments or by cytosolic 
nucleases66. In this context, pDNA degradation will largely depend on its presentation, 
where naked pDNA would be more susceptible to degradation compared to complexed 
FLR-associated pDNA67. It is likely that any decomplexation of pDNA, which will be 
needed for its transcription, would be proportional to the amount of pDNA delivered 
independent of specific uptake route68.  
 
3.12. GET Magnetofected complexes internalize rapidly into vesicles. We further 
investigated the trafficking of nanocomplexes by tracking the uptake of labelled pDNA. 
Intracellular localization of Rh-pDNA (pGLuc) was imaged by confocal microscopy after 
delivery with FLR (FLR-DNA) or FLR-MNPs under a magnetic field (FLR-DNA-MNPs) 
after 30 min (Figure 6A), 60 min (Figure 6B) and 24 hours (Figure 6C) transfection. At the 
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end of each incubation time, cells were washed with PBS, fixed and stained with Alexa 
Fluor 488 Phalloidin and DAPI to identify actin cytoskeleton and nucleus, respectively69.  
Merged fluorescent images showed minimal fluorescence within or on cell membranes 
after 30 min with FLR-DNA nanocomplexes; however, when delivered as FLR-DNA-
MNPs under a magnetic field, large numbers of fluorescent particles could be observed 
localized around cell boundaries and attached to membrane surfaces (Figure 6A). After 
1 hour delivery, discrete fluorescent particles could be detected with FLR-DNA 
nanocomplexes; however, these were less abundant when compared FLR-DNA-MNP 
samples (Figure 6B). After 24 hours, most fluorescence was detected within cells 
concentrated around the nucleus (Figure 6C). Fluorescence was localized as discrete 
foci, as opposed to homogeneously distributed throughout the cytosol, suggesting the 
entrapment of the pDNA to intracellular vesicles70. Even though the vast majority of pDNA 
delivered was visible in perinuclear endosomes, significant reporter activity from pDNA 
demonstrates that some must be correctly localized for nuclear expression.  
We therefore demonstrated progressive interaction with and transfer through cell 
membranes over time, irrelevant of the complex or targeting to cells. 
 
4. Conclusions. 
In this work, the use of GET peptide, FLR, to efficiently deliver pDNA on a MNP-based 
vector under the influence of a magnetic field has been optimized and characterized. FLR-
DNA-MNP nanocomplexes were able to significantly improve reporter gene expression 
after short incubations (>5 seconds) in the presence of a magnetic field compared with 
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no magnetic field or FLR-DNA nanocomplexes alone. Effect of GET magnetofection on 
cellular entry mechanism, pDNA stability inside the cell and cellular viability were also 
assessed. The system appears to be cytocompatible and pDNA is stable when uptaken; 
potentially through a variety of endocytotic pathways.  
Importantly nearly all cells could be loaded with detectable amounts of pDNA within 5 
min, and some level of transgene expression was detectable even with 5 second 
exposures with FLR-DNA-MNP nanocomplexes in the presence of a magnetic field. The 
most impactful observation from our study is the rapidity and zonality of transfection using 
the magnetic system. We foresee translation of our system in vitro for applications where 
regional delivery or speed is technically important, and in vivo using external static 
magnets or internal focusing of magnetic resonance to target tumours or specific organs 
or tissues. 
When treated with endocytosis inhibitors FLR-DNA and FLR-DNA-MNP nanocomplexes 
showed significantly lower pDNA uptake in hypertonic medium compared to the other 
inhibitors, suggesting a sizable contribution of clathrin-dependent endocytosis on pDNA 
uptake. Interestingly, MBCD, which is involved in cholesterol depletion from the cell 
membrane, significantly affected pDNA uptake during GET magnetofection in the 
presence of a magnetic field, more so than the other inhibitors, suggesting an important 
role of caveolae mediated endocytosis when complexes are targeted. Degradation of 
delivered pDNA seems to be consistent across the complexes over a 24 hour period 
suggesting that complex and uptake mechanism do not play significant roles in pDNA 
intracellular trafficking, more likely, pDNA degradation rate is proportional to intracellular 
concentration.  
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Finally, confocal imaging confirmed the presence of pDNA localized around the 
boundaries of the cell as well as some degree of internalization at early time points (30 
and 60 min) using magnetofection, but very little uptake for FLR-DNA nanocomplexes. 
After 24 hours, pDNA could be seen internalized around the cell nucleus or confined to 
vesicles in the cytoplasm for all complexes tested. The principle behind magnetofection 
is the concentration of the cargo to cell population either in vitro or in vivo. Our findings 
indeed suggest that MNP–containing nanocomplexes under a magnetic field quickly 
concentrate pDNA onto the cell surface and by doing so alter uptake kinetics and 
mechanism, however, we found no evidence that MNPs except for targeting play any 
further role in gene transfer.  
In summary, these results show that GET system can efficiently be used for 
magnetofection. Insight into mechanisms of uptake during GET magnetofection may aid 
the design of future magnetic gene vectors, and to develop novel approaches to target 
genetic therapeutics with magnetic fields.  Magnetic field-guided local transfection and 
focused in vivo gene delivery may now be possible by combining nanocomplex 
magnetofection with GET-mediated non-viral gene delivery. 
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Figure 1.
Figure 1. GET-Magnetofection complex formulation. A. FLR is formed of a heparan
sulphate glycosaminoglycan binding domain, composed of the FGF2 heparin binding
domain B (red); an amphipathic region termed LK15 (blue) and a cell penetrating peptide
(CPP), 8R (purple). B. Nanoparticle complexation: the positively charged residues (N) in
the FLR peptide sequence interact electrostatically with the negatively charged (P)
phosphate groups of pDNA or dextran-coated MNPs forming nanocomplexes. C.
Percentage of YO-PRO-1-DNA fluorescence at increasing the peptide ratios (N/P). Graph
represent mean ± s.d. (n= 3 technical replicates). D. Rhodamine (Rh)-pDNA conjugated
with FLR (N/P 6) was incubated with MNPs (5, 10, 20 and 40 µg MNPs/ 1 µg DNA) in
water. Percentage of DNA absorbed was calculated relative to the total amount of DNA.
Dots represent mean percentage of DNA adsorbed ± s.d. (n=9 technical repeats). E.
Percentage of pDNA complexed by FLR at increasing concentrations of MNPs (5, 10, 25
and 50 µg MNPs/ 1 µg DNA). YO-PRO-DNA complexed with FLR (without MNPs) taken
as 100% complexation. Bars represent mean complexed DNA ± s.d. (n=3 technical
repeats). F. Gaussia luciferase expression in NIH3t3 cells after transfection with FLR-
DNA-MNPs at N/P 4, 5 and 6 at increasing concentrations of MNPs (5, 10, 25 and 50 µg
of MNPs per µg of DNA). Cells treated with FLR-DNA only at N/P 4, 5 and 6 were used as
controls (0 µg MNPs/µg). Bars represent Relative Light Units, RLU ± s.d. (*p<0.05,
***p<0.001, ****p<0.0001, significance between treatments at N/P ratio 6 compared with
same treatment at N/P 4 and 5. Tukey’s multiple comparisons test, n=3 biological
replicates).
Figure 2. GET Magnetofection allows rapid transfection without cytotoxicity. A. Gaussia
luciferase expression in NIH3t3 cells after 1 hour or 24 hours delivery. pDNA (pGLuc) was delivered
with MNPs, FLR and FLR-MNPs in the presence or absence of a magnet. For all formulations 0.5 µg
of DNA were delivered, MNPs complexes were formulated at 5 µg MNPs/ 1 µg of DNA. FLR-DNA
ratio was constant at N/P 6. (n=4 biological replicates, ** p<0.01, comparison between transfection at
1 hour and 24 hours, Sidak’s multiple comparisons test; $$ p<0.01, comparison between transfection
at 1 hour, Tukey’s multiple comparisons test). B. Cumulative life cell number count and C. Cell
viability after incubation with FLR based complexes. NIH3t3 cells were treated with FLR-DNA and
FLR-DNA-MNPs with and without the presence of an external magnetic field (magnet) for 1 hour.
Values represent mean percentage of cell viability ± s.d (n=3 biological replicates).
Figure 2.
Figure 3. Rapid and efficient GET Magnetofection with low exposure times. A. Gaussia
luciferase expression after 5, 15, 30 and 60 min transfection/magnetofection with FLR (FLR-DNA)
and FLR and MNPs, FLR-DNA-MNPs with/without the application of a magnetic field. MNPs
complexes were formulated at 5 µg MNPs/ 1 µg of DNA. FLR-DNA N/P 6. Bars represent mean
values ± s.d, 1 technical replicates. (****p<0.0001 compared to treatments in the same group,
&p<0.01 compared to FLR-DNA, Tukey’s multiple comparisons test, n=3 biological replicates). B.
Percentage and C. Mean intensity of rhodamine (Rh) positive NIH3t3 cells after Rh-DNA after
transfection/magnetofection for 5, 15, 30 and 60 min. Rh-pDNA was delivered with FLR (FLR-DNA)
and FLR and MNPs, FLR-DNA-MNPs with/without the application of a magnetic field. MNPs
complexes were formulated at 5 µg MNPs/ 1 µg of DNA. FLR-DNA N/P 6. Values represent mean ±
s.d. n=3 biological replicates. D. Iron cell association in NIH3t3 cells after 5, 15, 30 and 60 min
magnetofection with FLR-DNA-MNPs with/without the application of a magnetic field. MNP
complexes were formulated at 5 µg MNPs/ 1 µg of DNA. FLR-DNA N/P 6. Bars represent mean
values ± s.d. n=3 biological replicates (*** p<0.001, **** p<0.0001, comparison between
magnetofection with and without magnets, Sidak’s multiple comparison’s test).
Figure 3.
Figure 4.
Figure 4. Rapid and efficient transgene targeting with GET magnetofection using static magnetic
field. A. eGFP expression after 15, 30 and 60, 120 and 1440mins (24hours) transfection/magnetofection
exposure. After transfection cells were washed with PBS to remove any unbound DNA complex. 0.5 µg of
DNA were delivered with FLR-DNA and FLR-DNA-MNP complexes with/without the application of a
magnetic field. MNPs complexes were formulated at 5 µg MNPs/ 1 µg of DNA. FLR-DNA ratio was
constant at N/P 6. n=3 biological repeats, 3 technical replicates. Bar is 100µm. B. Quantitation of eGFP
positive percentage from A C.i. Schematic of the system used to target a fixed coverslip in a larger
monolayer cell culture, defining IN (under magnetic field) and OUT (no magnetic field) regions. ii.
Demonstration of targeting GET magnetofection in a 15min exposure with a static magnet. Bar is 100µm.
D. Quantitation of eGFP positive cell percentage from C.ii. By flow cytometry. n=3 biological repeats, 3
technical replicates.
Figure 5. Effect of endocytosis inhibitors on pDNA cell association and uptake by GET
Magnetofection. Percentage of rhodamine (Rh) positive NIH3t3 cells after Rh-DNA after
transfection/magnetofection with FLR (FLR-DNA) and FLR and MNPs, FLR-DNA-MNPs
with/without the application of a magnetic field in the presence of endocytosis inhibitors. Final
concentration of inhibitors: methyl-B-cyclodextrin (MBCD) 5 mM, 5(N-ethyl-N-isopropyl)
amiloride 100 µM and sucrose 0.45 M. Cells were exposed to the inhibitors/4oC for 1 hour. The
effect of inhibitors was tested on DNA cell association (A) and DNA cell uptake (B) 24 hours
post-delivery. Bars represent average percentage of rhodamine labelled cells ± s.d. n= 6
biological replicates (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, comparison to control,
Tukey’s multiple comparisons test).
Figure 5.
Figure 6. Rapid uptake of pDNA by GET Magnetofection. Confocal Laser Scanning Microscopy
(CLSM) images of Rh-labelled DNA in NIH3t3 cells after A. 30 min, B, 60min or C. 24 hours
delivery. Cells were transfected with FLR-DNA and FLR-DNA-MNPs in the presence of a magnetic
field. Cells were treated with 1 µg of Rh-pDNA (pCMV-GLuc2) at N/P ratio 6 and optimal MNPs
mass ratio 5 µg MNPs / 1 µg DNA for 30 min. After incubation, unbound complex was removed with
PBS and cells were fixed with 3.7% PFA. Images show Rh-pDNA (red), cell nuclei stained with
DAPI (blue) and actin cytoskeleton stained with Alexa Fluor 488 Phalloidin (green). Scale bar 2 µm
Figure 6.
Merged
Merged
FLR/DNA ratio 
(N/P) 
1 2 3 4 5 6 7 8 9 10
FLR (nmol) 0.17 0.34 0.51 0.68 0.85 1.02 1.20 1.37 1.54 1.71
Amount of FLR peptide needed to form a peptide-DNA complex at the indicated charge ratio (N/P) for
1μg of pDNA of approximately 5800 bp. N/P charge ratio was calculated based on the number
positively charged amine groups of the FLR molecule (+18).
Table 1. Formulation of FLR-DNA nanoparticles.
MNPs 
(µg/µg 
DNA)
DNA (µg)
FLR-DNA¥ 
incubation 
time (min)
OptiMEM 
(µl)*
MNPs (µl of 10 
mg/ml stock)§
FLR/DNA + 
MNPs 
incubation 
time (min)
Media per 
well (µl)
Total transfection 
volume (media+ 
OptiMEM)(µl)
5 0.5 15 2x12.5 0.25 15 100 125
10 0.5 15 2x12.5 0.5 15 100 125
25 0.5 15 2x12.5 1.25 15 100 125
50 0.5 15 2x12.5 2.5 15 100 125
Table 2. FLR-DNA-MNPs complexation for 0.5 μg of DNA per transfection on a 48 well-plate format.
Scalable to other well-plate formats.
¥ Amount of FLR added was adjusted according to N/P ratio (Table 1)
* FLR was diluted to a total volume of 12.5 μl in OptiMEM. DNA was diluted to a total volume of 12.5 μl
in OptiMEM. DNA solution was added to FLR solution and mixed thoroughly to facilitate particle
formation.
§ MNPs volume was added straight into the FLR-DNA solution and mixed thoroughly.
Table 2. Formulation of FLR-DNA-MNPs nanoparticles for in vitro magnetofection.
The size (DH) and zeta potential bare MNPs, FLR-DNA complex, FLR
functionalized MNPs, DNA functionalised MNPs and MNPs functionalized with
the FLR-DNA complex. Measurements were performed in distilled water in
water (dH2O) were measured using Malvern Nanosizer Nano ZS. Values
represent mean ± s.d.
* Z-average hydrodynamic diameter extracted by cumulant analysis of the data.
¥ Polydispersity index (PDI) from cumulant analysis.
Table 3. Physical characterization of GET-Magnetofection complexes vectors for 
pDNA delivery. 
DH (nm)* PDI¥ Zeta potential (mV)
MNPs 225.1 ± 4.4 0.18 ± 0.03 -20.7 ± 0.5
FLR-DNA 124.6 ± 2.9 0.24 ± 0.002 49.8 ± 1.1
MNPs-FLR 228.0 ± 4.7 0.16 ± 0.02 35.3 ± 0.8
MNPs-DNA 239.1 ± 3.9 0.24 ± 0.01 -31.6 ± 0.8
FLR-DNA-MNPs 244.7 ± 8.5 0.21 ± 0.01 34 ± 1
